1. Home
  2. IBRX vs BXSL Comparison

IBRX vs BXSL Comparison

Compare IBRX & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

N/A

Current Price

$8.28

Market Cap

6.1B

Sector

Health Care

ML Signal

N/A

Logo Blackstone Secured Lending Fund of Beneficial Interest

BXSL

Blackstone Secured Lending Fund of Beneficial Interest

N/A

Current Price

$24.01

Market Cap

5.6B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
IBRX
BXSL
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
5.6B
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
IBRX
BXSL
Price
$8.28
$24.01
Analyst Decision
Strong Buy
Buy
Analyst Count
6
8
Target Price
$12.50
$28.13
AVG Volume (30 Days)
31.9M
2.5M
Earning Date
01-01-0001
05-28-2026
Dividend Yield
N/A
12.86%
EPS Growth
38.71
N/A
EPS
N/A
2.46
Revenue
$113,288,000.00
N/A
Revenue This Year
$88.57
$2.05
Revenue Next Year
$146.98
N/A
P/E Ratio
N/A
$9.74
Revenue Growth
668.31
N/A
52 Week Low
$1.83
$23.30
52 Week High
$12.43
$33.73

Technical Indicators

Market Signals
Indicator
IBRX
BXSL
Relative Strength Index (RSI) 52.60 42.36
Support Level $2.27 $23.30
Resistance Level $12.43 $27.04
Average True Range (ATR) 1.07 0.64
MACD -0.31 0.05
Stochastic Oscillator 11.91 42.41

Price Performance

Historical Comparison
IBRX
BXSL

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.

Share on Social Networks: